Takeaways: Astellas’ Canadian real-world evidence strengthens the implementation case for CLDN18.2-targeted therapy by demonstrating a testing network across 13 validated centres, with a 6.1-day...
Browsing Tag: gastroesophageal junction cancer
Takeaways: Astellas’ Canadian real-world evidence strengthens the implementation case for CLDN18.2-targeted therapy by demonstrating a testing network across 13 validated centres, with a 6.1-day...